Bioline RX News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.05.17	Midmarket CIOs Honor Netreo With an XCellence Award at the 2017 MES Conference (PR Newswire)
04.05.17	Impact Labs Expands Software Offering for High-Performance Wealth Management: Smart Beta and Factor-Tilt (PR Newswire)
03.05.17	BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA (PR Newswire)
28.04.17	How These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma (PR Newswire)
05.04.17	BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares (PR Newswire)
31.03.17	BioLineRx Prices $25 Million Underwritten Public Offering (PR Newswire)
30.03.17	BioLineRx Announces Underwritten Public Offering of its American Depositary Shares (PR Newswire)
27.03.17	BioLineRx's AGI-134 to be Presented at AACR 2017 (PR Newswire)
23.03.17	BioLineRx Reports Year End 2016 Financial Results (PR Newswire)
23.03.17	BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline (PR Newswire)
20.03.17	BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment (PR Newswire)
16.03.17	BioLineRx to Report Annual 2016 Results on March 23, 2017 (PR Newswire)
07.02.17	BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14 (PR Newswire)
17.01.17	BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer (PR Newswire)
04.01.17	BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco (PR Newswire)
05.12.16	BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016 (PR Newswire)
22.11.16	BioLineRx Reports Third Quarter 2016 Financial Results (PR Newswire)
21.11.16	BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company (PR Newswire)
26.09.16	FDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE (RTTNews)
30.03.16	FDA Panel Backs ACAD, AUPH Awaits Data In Q3, CTRV Abuzz (RTTNews)
24.03.16	Odyssey Hits The Mark, SPHS Awaits Data In Q2, TEVA Breathes Easy (RTTNews)
24.11.15	BMY's Opdivo Gets High-Five, XBIT Slammed For Messing Up Study, SMMT On Ascent (RTTNews)
06.11.15	EYEG Catches Investors' Eyes, FDA Approves GILD's HIV Pill, KBIO Lays Off Staff (RTTNews)
05.11.15	BioLineRx Announces Positive Results From First Part Of Phase 2 Trial In R/r AML (RTTNews)
18.08.15	ESPR On Track, INSY Gets FDA Date, It's A Thumbs Up For SGEN, RPTP (RTTNews)
17.08.15	BioLineRx Initiates Phase 2b Trial In Acute Myeloid Leukemia (RTTNews)
05.05.15	ACRX Deeply Pained, ISIS Cuts A Deal, AQXP Reaches Enrollment Target (RTTNews)
11.03.15	BioLineRx Reports Positive Pre-clinical Results For BL-9020 In Type 1 Diabetes (RTTNews)
07.01.15	ALKS Moves Forward, KBIO Craters, GILD Opens Wallet, TRVN For The Long Haul (RTTNews)
24.12.14	BLRX Does A Deal, CRMD Enters Arabia, IG Exceeds Goal, See What's New In GRANIX (RTTNews)
16.12.14	Look Who's Buying 12.8% Stake In BLRX... (RTTNews)
21.08.14	BioLineRx Receives Notice Of Allowance For US Patent On BL-7010 (RTTNews)
07.08.14	BDSI Hoping To Deliver, MDCO Gets FDA Nod, TXMD On Watch, Busy Days Await NVAX (RTTNews)
30.05.14	BioLineRx Signs Purchase Agreement With Lincoln Park Capital - Quick Facts (RTTNews)
11.03.14	La Jolla Shines, ETRM Gets New Decision Date, NWBO Going North, RGDO Explodes (RTTNews)
10.03.14	BioLineRx: BL-7010 Completes Dose-escalation Stage Of Phase 1/2 Study (RTTNews)
04.03.14	BioLineRx Prices Public Offering Of 8.40 Mln ADSs At $2.50/ADS - Quick Facts (RTTNews)
18.12.13	BioLineRx Enrols First Patient In Phase 1/2 Trial Of BL-7010 (RTTNews)
17.12.13	ADHD Gets Attention, BioLife To Uplist Stock, TRGT Misses Goal, CEMP On A High (RTTNews)
16.12.13	BioLineRx Reports Early Phase 2 Results For Its BL-8040 - Quick Facts (RTTNews)
10.12.13	BioLineRx Presents Positive Preclinical Results Of BL-8040 - Quick Facts (RTTNews)
26.11.13	BioLineRx Announces Additional Phase 2a Results Of BL-7040 - Quick Facts (RTTNews)
19.11.13	BioLineRx Reports Publication Of Phase 1/2 Results In Stem Cell Mobilization (RTTNews)
05.11.13	ACUR To Meet With FDA, CYTX Does A Deal, NNVC Renews Contract, RGLS On Watch (RTTNews)
07.10.13	BioLineRx Announces Receipt Of Notice Of Allowance For Patent Covering BL-5010 (RTTNews)
24.09.13	BioLineRx Files Regulatory Submissions To Begin Phase 1/2 Trial For BL-7010 (RTTNews)
10.09.13	NBIX Craters, DHRM Gets Busy, TGTX, BLRX Compounds Get Orphan Drug Status (RTTNews)
09.09.13	BioLineRx Says BL-8040 Gets FDA's Orphan Drug Designation For Treatment Of AML (RTTNews)
09.09.13	BioLineRx's BL-8040 Receives Orphan Drug Designation for Treatment of AML (PR Newswire)
03.09.13	BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.37	2.88 %	K V
Part Grp Hldg	1’330.00	2.39 %	K V
Roche Hldg G	271.80	1.84 %	K V
Givaudan	3’941.00	1.52 %	K V
Novartis	91.64	0.75 %	K V
Geberit	502.80	-0.59 %	K V
CieFinRichemont	139.55	-0.99 %	K V
Swiss Re	133.25	-1.15 %	K V
Zurich Insur Gr	540.00	-1.32 %	K V
Kuehne+Nagel Int	203.00	-2.12 %	K V

Nachrichten zu Bioline RX Ltd. (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten